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Introduction: In 2012 a large epidemic of pertussis 
occurred in the Netherlands. We assessed pertus-
sis toxin (PT) antibody levels in longitudinal serum 
samples from Dutch 10–18 year-olds, encompassing 
the epidemic, to investigate pertussis infection inci-
dence.  Methods: Blood was sampled in October 2011 
(n = 239 adolescents), then 1 year (2012; n = 228) and 
3 years (2014; n = 167) later. PT-IgG concentrations were 
measured by immunoassay and concentrations ≥50 IU/
mL (seropositive) assumed indicative of an infection 
within the preceding year.  Results: During the 2012 
epidemic, 10% of participants became seropositive, 
while this was just 3% after the epidemic. The pertus-
sis acquisition rate proved to be sixfold higher during 
the epidemic (97 per 1,000 person-years) compared 
with 2012–2014 (16 per 1,000 person-years). In 2012, 
pertussis notifications among adolescents nationwide 
were 228/100,000 (0.23%), which is at least 40 times 
lower than the seropositivity percentage. Remarkably, 
17 of the 22 seropositive participants in 2011, were 
still seropositive in 2012 and nine remained seroposi-
tive for at least 3 years. Discussion: Longitudinal stud-
ies allow a better estimation of pertussis infections 
in the population. A PT-IgG concentration ≥50  IU/mL 
as indication of recent infection may overestimate 
these numbers in cross-sectional serosurveillance and 
should be used carefully.
Introduction 
Pertussis, caused by the bacterium  Bordetella per-
tussis, is a vaccine preventable infection of the upper 
respiratory tract, which is particularly severe in young 
infants [1,2]. Despite high vaccination coverage, 
pertussis has re-emerged since the 1990s in most 
industrial countries [3-7].
Serological surveillance studies are a tool to inves-
tigate the pertussis infection rate in the population 
by determining serum IgG antibody concentrations 
against pertussis toxin (PT). PT is one of the major vir-
ulence factors during infection and is only expressed 
by  B. pertussis  [8-11]. A cross-sectional population-
based serosurveillance study conducted in the 
Netherlands in 2006–2007, showed that 9% of adoles-
cents (10–18 years of age) and adults (> 18 years of age) 
contained a PT serum antibody concentration ≥  50  IU/
mL, suggestive for a pertussis infection in the pre-
ceding year [12]. In contrast, the number of reported 
pertussis cases during that same period was only 
0.03%  (30  cases/100,000 persons) [13]. More accu-
rate information regarding pertussis acquisition can be 
provided by longitudinal studies. Furthermore, longi-
tudinal studies may also illustrate the course of anti-
body kinetics during pertussis infections and between 
epidemics.
In 2011–2012, a longitudinal meningococcal vaccina-
tion trial was conducted among Dutch adolescents [14]. 
By coincidence, two blood samples from that study 
were collected encompassing the largest pertussis epi-
demic in the Netherlands since its resurgence. During 
that 2012 epidemic, the number of reported pertussis 
cases increased to 83/100,000 persons in the whole 
Dutch population [13]. In addition to the samples from 
2011 and 2012, a follow-up sample was collected in 
2014, resulting in three longitudinal samples over a 
period of three years. We determined PT specific IgG 
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antibody concentrations in these samples to investi-
gate the (sub-clinical) pertussis infection rate among 
adolescents during and after the 2012 epidemic and to 
explore antibody kinetics after pertussis infection.
Methods 
Study design and participants
The samples used in this study originated from a phase 
IV meningococcal serogroup C conjugated (MenCC) 
booster vaccine trial [14,15]. In short, adolescents aged 
10, 12 and 15 years were vaccinated in October 2011 with 
a MenCC booster vaccination and blood samples were 
collected before, 1  month, 1  year and 3  years follow-
ing vaccination. Participants were randomly selected 
from four different municipalities in the Netherlands. 
Samples collected one month post-booster vaccination 
were excluded in the current study. Time of sampling is 
further indicated by year of sampling.
The study was approved by the Medical research 
Ethics Committees United (MEC-U, Nieuwegein, the 
Netherlands). Written informed consent was obtained 
from both parents and from participants aged 12 years 
and older. The trial was registered at the European 
Clinical Trials Database (2011–000375–13) and at the 
Dutch Trial Register (www.trialregister.nl; NTR3521).
Vaccination background
All participants were vaccinated according to the Dutch 
national immunisation program (NIP), including four 
vaccinations with the whole-cell pertussis combina-
tion vaccine (DTwP-IPV-Hib, the Netherlands Vaccine 
Institute (NVI), Bilthoven, the Netherlands) in a 3  +  1 
schedule in the first year of life. In addition, the 10 and 
12 year-olds received an acellular pertussis vaccine in 
combination with a DT-IPV booster (NVI) at 4  years of 
age.
Pertussis toxin specific antibody concentration
Serum PT-IgG antibody concentrations were measured 
using the fluorescent-bead-based multiplex immuno-
assay as described [16]. The in-house pertussis refer-
ence sample was previously calibrated to United States 
reference pertussis antiserum human lot 3 (Center 
for Biologics Evaluation and Research, Food and 
Drug Administration, Silver Spring, Maryland, United 
States). To express PT-IgG concentration in interna-
tional units (IU) per mL, we extensively compared the 
in-house reference to the World Health Organization 
international standard (pertussis antiserum 1stint-
ernational standard, 06/140, National Institute for 
Biological Standards and Control, Potters Bar, United 
Kingdom [17]). We found a small difference with the 
previous calibration resulting in a correction of a factor 
0.8 for PT antibody levels. This implies that the level 
for recent  B. pertussis  infection changes from 62.5 
enzyme-linked immunosorbent assay units (EU) per mL 
to 50 IU/mL in our laboratory [12,18]. A PT-IgG concen-
tration of ≥ 50  IU/mL was used as a cut-off for pertus-
sis infection in the preceding year [12] with a specificity 
of 95% and a sensitivity of 80%, and indicated here 
as seropositive. Furthermore, a PT-IgG concentration 
of ≥ 100  IU/mL was used as cut-off for pertussis infec-
tion in the preceding 6 months [12], with a specificity of 
99% and sensitivity of 70% [19].
Pertussis surveillance data
To compare the number of seropositive study partici-
pants with the reported notifications of all Dutch ado-
lescents of 10–18  years of age, pertussis notification 
data were extracted from the mandatory national sur-
veillance notification system for vaccine-preventable 
diseases in the Netherlands, as previously described 
[7]. Then, based on the age of the study participants, 
all cases who matched in age were grouped per year. In 
this study, the provided pertussis incidence data were 
obtained from November to October, as the serology 
data were also determined in the month October. For 
example, incidence data of all Dutch 11, 13 and 16 year-
olds, which were reported between November 2011 and 
October 2012, were used for the comparison with serol-
ogy data at sampling time point October 2012, while 
incidence data of all Dutch 13, 15 and 18  year-olds 
reported between November 2013 and October 2014 
were used to compare with the serology data at sam-
pling time point October 2014.
Statistical analyses
Differences in PT-IgG antibody concentrations between 
the age groups were tested with one-way analysis of 
variance (ANOVA). PT-IgG antibody concentrations were 
also dichotomised to study differences in proportion of 
participants with a PT-IgG concentration ≥ 50  IU/mL or 
with a PT-IgG  ≥  100  IU/mL between time points, and 
were tested using McNemar tests. A p-value below 0.05 
Figure 1
Absolute number of reported pertussis cases for Dutch 
adolescents 10 to 18 years of age, January 2010–December 
2015 (n = 13,127 total cases)
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was considered statistically significant. Chi-squared 
tests were used to assess difference according to sex 
within the study population.
The participants who became seropositive during the 
course of the study were considered to have been 
infected with  B. pertussis. The acquisition rates per 
1,000 person-years between October 2011 and October 
2012 and between October 2012 and October 2014 
were determined by dividing the number of new per-
tussis infected individuals by the total person-time in 
years of all initially negative individuals [20].
Results 
Study population
Of the 268 participants enrolled in the original study, 
29 had not given permission for sample analysis 
beyond the objectives for the meningococcal vaccine 
trial and were therefore excluded from analysis [14]. 
From the 239 participants available for analysis, blood 
samples had been collected in 2011 (n  =  239), 2012 
(n = 228; 95.4%) and 2014 (n = 167; 69.9%). In total 72 
participants were lost to follow-up during the course of 
the study. These were distributed evenly across all age 
groups. Baseline characteristics are listed in  Table 1. 
There were no differences according to sex within the 
overall study population (p = 0.134). At the beginning 
of the study (2011), the PT-IgG geometric mean concen-
trations (GMCs) were similar between the age groups 
(GMC of the 10, 12 and 15 year-olds was 5.4, 6.8, and 
6.7 IU/mL respectively, p = 0.420), and between males 
and females (GMCs were 5.8 and 6.7  IU/mL, respec-
tively, p = 0.276).
Pertussis surveillance data
The number of notified pertussis cases in Dutch ado-
lescents aged 10–18 years for the period 2010–2015 is 
depicted in Figure 1. During the 2012 epidemic, a two-
fold increase in the number of reported pertussis cases 
was seen in the respective age range (10–18  years 
of age) of the study participants, with 115/100,000 
(0.12%) cases between November 2010 and October 
2011, and 228/100,000 cases (0.23%) between 
November 2011 and October 2012. After the epidemic, 
between November 2013 and October 2014, the num-
ber of reported cases was 80/100,000 (0.08%).
Pertussis toxin IgG seropositivity per year
In October 2011, 9% (22/239) of the participants had 
a PT-IgG concentration ≥  50  IU/mL. The proportion of 
participants with a PT-IgG concentration ≥  50  IU/mL 
in 2012 was significantly higher compared with 2011 
(17%, 39/228; p  =  0.002). In 2014, 13% (21/167) of 
Figure 2
Follow up at different time points of Dutch study participants aged between 10 and 18 years for pertussis infection, the 
Netherlands, 2011–2014 (n = 239 initial participantsa)
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the participants had a PT-IgG concentration ≥  50  IU/
mL (p = 0.238 and p = 0.167 compared with 2011 and 
2012 respectively). The proportion of participants 
with a PT-IgG concentration ≥  100  IU/mL was highest 
in 2012 (12%,  27/228) compared with 2011 and 2014 
(5%  (13/239), p  =  0.004 and 5%  (8/167), p  =  0.017, 
respectively). For both cut-off PT-IgG concentrations, 
no differences in seropositivity were found according 
to sex.
New pertussis infections and acquisition
Of the initially negative participants in 2011, 10% 
(22/217) were seropositive in 2012, resulting in an 
acquisition rate of 97 per 1,000 person-years (Figure 
2a). Of the initially negative participants in 2012, 3% 
(6/184) became seropositive in 2014 (Figure 2a). The 
acquisition rate for the period 2012–2014 was 16 per 
1,000 person-years. During the 2012 epidemic, the 
percentage of newly seropositive participants was 44 
times higher than the percentage of reported pertussis 
cases in these age groups. 
Kinetics of pertussis toxin specific antibody 
concentrations
Of the 22 participants who became seropositive 
(≥  50  IU/mL) in 2012, 20 had a PT-IgG concentra-
tion < 10 IU/mL in 2011. Eighteen of these 22 participants 
had a PT-IgG concentration > 100  IU/mL in 2012 (red 
dots Figure 3a). All participants who became seroposi-
tive between 2012 and 2014 (n = 6) had PT-IgG concen-
trations < 10 IU/mL in 2012 (red dots in Figure 3b).
PT-IgG levels in the samples of the 22 seropositive par-
ticipants in 2011 declined on average 1.8 fold between 
2011 and 2012 (orange and green dots in  Figure 3a), 
and five samples dropped below 50  IU/mL in 2012 
(green dots in  Figure 3a). Three seropositive partici-
pants in 2011 showed a 1.2–1.3 fold increase in PT-IgG 
concentrations in 2012. An average of 3.0 fold antibody 
decay was observed between 2012 and 2014 in the 39 
seropositive participants of 2012 (orange and green 
dots in Figure 3b).
Duration of seropositivity
In 2012, 17 of the 22 participants with a PT-IgG con-
centration ≥  50  IU/mL in 2011 maintained a PT-IgG 
concentration ≥ 50 IU/mL (Figure 2a). Of the 39 partici-
pants with a PT-IgG concentration ≥  50  IU/mL in 2012, 
15 maintained this PT-IgG concentration ≥  50  IU/mL in 
2014. Furthermore, nine of the 22 participants with a 
PT-IgG concentration ≥  50  IU/mL in 2011 maintained a 
PT-IgG concentration ≥ 50 IU/mL over the 3-year course 
of the study (Figure 2a). One participant (1/13) main-
tained a PT-IgG concentration ≥  100  IU/mL for 3  years 
(Figure 2b). In 2012, nine of the 13 participants in 
2011 maintained a PT-IgG concentration ≥  100  IU/mL 
Figure 3
Individuals’ paired pertussis toxin (PT) specific IgG concentrations (IU/mL) in A) 2011 vs 2012, and B) 2012 vs 2014, the 
Netherlands, 2011–2014 (n = 239 initial participantsa)
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and three of the 27 participants in 2012 maintained a 
PT-IgG concentration ≥ 100 IU/mL in 2014 (Figure 2b).
Discussion 
In this study, PT specific antibody levels in longitu-
dinal samples from adolescents aged 10–18  years 
encompassing the pertussis epidemic of 2012 in the 
Netherlands were assessed. The pertussis infection 
acquisition rate in the study population was six times 
higher during the 2012 epidemic (97 per 1,000 per-
son-years), compared with the low-epidemic period of 
2013–2014 (16 per 1,000 person-years). Interestingly, 
17 of the 22 seropositive participants in 2011 were still 
seropositive in 2012 and nine remained seropositive 
for three years.
In cross-sectional serosurveillance studies a PT-IgG 
concentration of ≥ 50 IU/mL is defined as cut-off for B. 
pertussisinfection in the preceding year [11]. By apply-
ing this cut-off to our cohort, even in low-epidemic 
years (2011 and 2014) compared with 2012, already 9 
(22/239) to 13% (21/167) of the study participants could 
be considered to be recently infected with B. pertussis. 
This is in line with the cross-sectional serosurveillance 
study conducted in 2006–2007 in the Netherlands 
[12] and with other studies from Australia (2007) [21], 
Belgium (2012) [22], and Norway (2004) [23]. At the 
end of the pertussis epidemic in 2012, the propor-
tion of seropositive adolescents in our cohort almost 
doubled to 17% (39/228). Moreover, 10% (22/217) of 
the participants had become seropositive in 2012. 
This indicates that these participants were actually 
infected with  B. pertussis  during the epidemic and 
that pertussis circulation was high. In contrast, only 
3% (6/184) of the participants became seropositive 
between 2012 and 2014. Acquisition rates were 
determined based on initial seronegative participants, 
which included the participants who were unavailable 
for additional blood samplings during the rest of the 
study period. Approximately 30% (72/239) of the 
recruited participants were lost to follow-up between 
2011 and 2014. The percentage of participants who 
became seropositive during the study could possibly 
have been even higher than indicated, and thereby 
also the pertussis acquisition rate, as we do not know 
the status of these participants.
The high pertussis acquisition rate in adolescents 
observed during the epidemic could be caused by the 
relatively easy spreading of B. pertussis via respiratory 
droplets [24] and the tendency of adolescents to mix 
especially with people of the same age [25]. However, 
in a cross-sectional population-based serosurveillance 
study no differences were found in the percentage of 
seropositive participants between adolescents, adults 
and elderly [12]. This suggests that pertussis acquisi-
tion might be comparable for all individuals above 
9  years of age due to high transmission through all 
kinds of routes.
Following individual antibody concentrations, we 
noticed limited antibody decay in seropositive samples 
during the three year follow-up. Nine of the 22 initially 
seropositive participants in 2011 remained seroposi-
tive for at least three years. This was in agreement 
with a previous study, where the half-life of specific 
PT-IgG antibodies after infection was estimated to be 
ca 17 months [26]. Although natural boosting of these 
nine participants during the study period cannot be 
excluded, particularly during the epidemic, no increase 
in PT-IgG antibody concentration was found between 
2012 and 2014. This finding emphasises that the use 
of a PT-IgG concentration of ≥ 50 IU/mL as a cut-off for 
pertussis infection in the preceding year leads to an 
overestimation of pertussis infections. Moreover, a 
PT-IgG antibody concentration above 100  IU/mL, used 
as indication of pertussis infection in the preceding six 
months [11,12], will also result in an overestimation of 
pertussis infections. At this moment, it seems unclear 
which PT-IgG cut-off is appropriate to use as an indica-
tion for recent pertussis infection.
Since the scope of the original study was to inves-
tigate immune responses to a meningococcal sero-
group C booster vaccination, information about clinical 
manifestation and PCR confirmation of pertussis was 
unavailable. Therefore, we do not know from the sero-
positive participants if the pertussis infection involved 
symptoms or not and if they were able to transmit  B. 
pertussis  to others. Presumably most of the infected 
participants were asymptomatic or only had mild 
symptoms, as the majority of pertussis infections 
do not cause severe morbidity in adolescents [27]. It 
should be noted that pertussis immunisation schedules 
Table 
Characteristics of participants at the beginning of the study, the Netherlands, October 2011 (n = 239 participants)
Characteristics Overall 10 year-olds 12 year-olds 15 year-olds
Number of participantsa 239 81 82 76
Mean age in years in October 2011 (SD) NA 9.9 (0.3) 12.0 (0.3) 15.0 (0.3)
Number of participants of male sex (%) 120 (50) 34 (42) 42 (51) 44 (58)
NA: not applicable; SD: standard deviation.
a All participants were primed with a whole-cell pertussis combination vaccine four times in the first year of life (3 + 1 schedule). Ten and 12 
year-old participants received an acellular pertussis booster vaccine at 4 years of age.
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differed among the 10, 12 and 15 year-old age groups in 
this study. In 2001, a booster dose with the acellular 
pertussis vaccine at the age of four years was intro-
duced into the Dutch NIP. Participants aged 15  years 
at the beginning of the study, were five years of age 
in 2001 and therefore did not receive this booster. 
However, PT specific antibodies wane rapidly after 
acellular pertussis booster vaccination [28,29], and 
the booster vaccination has a limited duration of pro-
tection [30,31]. Moreover, no differences were found in 
PT-IgG concentrations between the three age groups at 
the beginning of the study (2011). Therefore, the effect 
of this acellular pertussis booster vaccination on the 
pertussis susceptibility of the participants in our study 
is likely limited.
Although our findings suggest that numbers of recent 
pertussis infections indicated in cross-sectional sero-
surveillance studies could be overestimated, we have 
provided evidence that the pertussis acquisition rate 
was 97 per 1,000 person/years during the 2012 pertus-
sis epidemic in our participants, over 40 times higher 
than the actually reported pertussis cases in these 
age groups. This suggests that also adolescents could 
form a large reservoir for  B. pertussis, which poses a 
possible threat for young unvaccinated infants who 
are especially at risk of developing severe illness [32]. 
In order to reduce this risk in neonates, several coun-
tries have implemented adolescent pertussis booster 
vaccinations next to maternal vaccination [33,34]. 
Unfortunately, whether (repeated) administrations of 
acellular pertussis booster vaccines can reduce the cir-
culation of B. pertussis remains uncertain. In a baboon 
model, Warfel et al. demonstrated that acellular per-
tussis vaccines protected against disease, but did not 
stop transmission and colonisation, while whole-cell 
pertussis vaccines protected against disease with 
rapid clearance of  B. pertussis[35]. Furthermore, indi-
viduals primed only with acellular pertussis vaccines 
in the first year of life have an increased risk of acquir-
ing pertussis compared with individuals vaccinated 
with at least one whole-cell pertussis vaccine [36-
38]. Nowadays, industrialised countries use acellular 
pertussis vaccines in the first year of life for priming. 
Therefore, enhanced surveillance of pertussis acquisi-
tion rates is crucial to monitor pertussis circulation in 
a population increasingly immunised with the acellular 
pertussis vaccine.
In conclusion, our results demonstrate that using lon-
gitudinal serological studies the acquisition rate of 
(sub-clinical) pertussis infections can be determined. 
Thereby, these studies can contribute to a better esti-
mation of the true pertussis incidence in the popula-
tion. Pertussis incidence in adolescents proved much 
higher than the number of reported pertussis cases, 
especially during an epidemic. This indicates that 
protection against infection conferred by the Dutch 
national immunisation programme is limited at that 
age. Furthermore, we highlighted to be cautious apply-
ing the current PT-IgG cut-off values in serosurveillance 
studies, as this will result in an overestimation of the 
numbers of pertussis infections.
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